不同引物介导的聚合酶链反应检测人乳头瘤病毒DNA

应用３对人乳头瘤病毒（ＨＰＶ）引物对１０７例各种宫颈标本进行了聚合酶链反应（ＰＣＲ）扩增。结果显示，共同引物（ＧＰ）扩增，有５８．８％（３０／５１）宫颈鳞癌，１００％（１４／１４）尖锐湿疣、１３．６％（３／２２）宫颈炎和１０％（２／２０）正常宫颈出现ＨＰＶ阳性。型特异性引物ＳＰ１６／ＳＰ１８扩增，有３７．２％（１９／５１）宫颈鳞癌２５．７％（５／１４）尖锐湿疣和５％（１／２０）正常宫颈出现ＨＰＶ１６型阳性，５．８％（３／５１）宫颈鳞癌为ＨＰＶ１８型阳性。进一步用ＳＰ１６ｂ引物扩增，没有１例ＨＰＶ１６ｂ亚型被发现。说明宜颈磷癌和尖锐湿疣与ＨＰＶ感染有关，结合应用共同引物和型特异性引物可作为ＨＰＶ检测与分型方法。     

应用共有引物的PCR法检测宫颈癌组织中的人乳头…

目前已知有６８种类型人乳头瘤病毒（ＨＰＶ），其中２７种类型ＨＰＶ与生殖道损害有关，ＨＰＶ１６，ＨＰＶ１８和宫颈癌关系密切。我们建立了快速敏感检测多型ＨＰＶ感染的方法，运用限制性片段长度多态性（ＲＦＬＰ），分析Ｌ１区共有引物ＰＣＲ扩增的产物。通过ＰＣＲ／ＲＦＬＰ法，我们检测５０例宫颈癌标本，ＨＰＶ阳性率为６４％；ＨＰＶ１６占４６％；ＨＰＶ１８占６％；ＨＰＶ１６和ＨＰＶ１８混合感染占６％。该法简便快速     

子宫颈癌组织中HPV16癌基因及p53基因的检测

利用ＨＰＶ１６Ｅ６、Ｅ７基因特异性引物，ＰＣＲ技术及抗癌基因ｐ５３外显子７特异性引物，ＰＣＲ－ＳＳＣＰ技术对３５例进展期子宫颈癌组织进行研究，发现：（１）３５例标本中ＨＰＶ１６Ｅ６、Ｅ７ＤＮＡ的总检出率为７１．４２％（２５例），其中同时检出Ｅ６、Ｅ７为３１．４２％（１１例），另外８．５７％及３１．４２％（３例及１１例）仅分别检出Ｅ６、Ｅ７序列。（２）全组未见１例有ｐ５３基因外显子７的点突变及等位基因缺失。该结果说明ＨＰＶ１６与本地区妇女子宫颈癌发生有密切关系，并且癌组织中ＨＰＶ１６Ｅ６、Ｅ７亚基因的分布是不均一的，ｐ５３基因外显子７的改变并不常见。在实验中我们还建立了使用生物素标记的ｄＵＴＰ进行ＰＣＲ－ＳＳＣＰ的技术。     

用聚合酶链反应检测食管癌组织中人乳头瘤病毒DNA

应用聚合酶链反应（ＰＣＲ）技术对汕头市区６８例食管癌的石蜡包埋标本进行人乳头瘤病毒（ＨＰＶ）ＤＮＡ序列检测，结果显示，ＨＰＶＤＮＡ总阳性率为６６．１８％（４５／６８），检出型别主要为ＨＰＶ６、１１、１６，检出率分别为２７．９４％、３６．７６％和２７．９４％，经统计学处理三型间无显著性差异；ＨＰＶ－１８及未定型别各占８．８２％。值得注意的是ＨＰＶ感染中多重感染占阳性病例的５３．３３％（２４／４５）。初步结果表明，汕头市食管癌高发区有较高的ＨＰＶ感染率，此与食管癌的发生，可能有密切关系。     

食管鳞癌HPV感染与病毒致癌基因E6的关系

目的：探讨人乳头瘤病毒（ＨＰＶ）与食管鳞状细胞癌的关系。方法：采用多重引物多聚酶链反应（ＰＣＲ）的免疫组化技术、对１０４例食管鳞癌进行ＨＰＶ ＤＮＡ和病毒癌基因Ｅ６蛋白检测。结果：ＨＰＶ ＤＮＡ阳性者占５０．９６％（５３／１０４），其中ＨＰＶ１６型ＤＮＡ４９．０６％（２６／５３），ＨＰＶ１８型 ＤＮＡ５．６％（３／５３），ＨＰＶ６／１１ ＤＮＡ７．５％（４／５３）；两上或三个类型的混合感染占３７．     

人喉癌组织中人乳头瘤病毒DNA的检测

目的为探讨喉癌与人乳头瘤病毒（ＨＰＶ）感染的关系和ＨＰＶ在喉癌中基因组型的分布与表达。方法应用聚合酶链反应技术（ＰＣＲ）制备非放射性探针标记物－地高辛标记ＨＰＶ共有引物探针,对１４６例喉不同病变的新鲜组织标本（喉癌６８例,喉其它病变４８例,正常喉组织３０例）,进行ＨＰＶ６,１１,１６,１８,３１,３３,３５,４２,５８共９型ＨＰＶＤＮＡ感染的检测;阳性者用多重引物ＰＣＲ方法分型。结果喉癌ＨＰＶ感染阳性率４５．６％（３１／６８）,喉癌颈转移淋巴结组织阳性率２０．０％（３／１５）,喉癌前病变阳性率１１．８％（２／１７）,声带息肉阳性率６．３％（１／１６）,１５例癌旁及１５例癌周正常喉组织均为ＨＰＶＤＮＡ阴性。ＨＰＶＤＮＡ型别分布在喉癌中以ＨＰＶ１６、１８型为主,喉良性病变中以ＨＰＶ６、１１型为主。结论喉癌发生与ＨＰＶ感染有关。     

人乳头瘤病毒与P 53协同致膀胱移行细胞癌关系的研究

目的 研究人类乳头瘤病毒（ＨＰＶ）６、１１、１６和１８型及Ｐ５３与膀胱移行细胞癌的关系。方法 采用聚合酶链反应（ＰＣＲ）方法检测了７５例膀胱移行细胞癌组织中ＨＰＶ的感染,免疫组化ＳＰ法检测Ｐ５３蛋白表达情况。结果 膀胱移行细胞癌组织中ＨＰＶ６、１１、１６和１８的阳性率分别为６．７％（５／７５）,５．３％（４／７５）,３３．３％（２５／７５）和６．７％（５／７５）。低危型ＨＰＶ（６或１１）阳性率为９．３％（７／７５）,高危型ＨＰＶ（１６或１８）阳性率为３４．７％（２６／７５）。同一膀胱癌组织中两种以上（包括两种）ＨＰＶ亚型感染８例,占１０．６％。ＨＰＶ６、１６和１８型之间感染阳性率在肿瘤有无转移组中差异显著（Ｐ〈０．０５）,ＨＰＶ１６、１８的阳性率在肿瘤病理分级中差异有极显著性（Ｐ〈０．０１）。ＨＰＶ ＤＮＡ型别     

人乳头状瘤病毒不同型别与宫颈病变的相关性研究

目的探讨人乳头状瘤病毒（ＨＰＶ）不同型别与宫颈病变性质的关系。方法应用ＰＣＲ技术和原位杂交方法对６１例宫颈上皮内瘤（ＣｅｒｖｉｃａｌｉｎｔｒａｅｐｉｔｈｅｌｉａｌＮｅｏｐｌａｓｉａＣＩＮ）和１２例宫颈鳞癌（ＳＣＣ）进行ＨＰＶ６Ｂ／１１、１６、１８ＤＮＡ检测。结果ＰＣＲ检测结果显示ＨＰＶ６、１１主要分布于低度鳞状上皮内病变（６１９％）和一部分ＣＩＮⅡ中（２０％），而在ＣＩＮⅢ和ＳＣＣ中检测不到；ＨＰＶ１６、１８的检出率随ＣＩＮ级别增高而增加，在ＳＣＣ中高达８３３％。原位杂交结果显示在低度鳞状上皮内病变中，地高辛（Ｄｉｇ）标记的ＨＰＶ６Ｂ／１１、１６、１８ＤＮＡ杂交物质在核中均呈细颗粒状，为“游离型”。上述杂交阳性信号形态亦出现于ＣＩＮⅡ的所有ＨＰＶ６Ｂ／１１及部分ＨＰＶ１６、１８型感染中，而ＣＩＮⅢ和宫颈鳞癌及部分ＣＩＮⅡ中，其杂交阳性信号均为非颗粒状的“整合型”。结论低度鳞状上皮内病变是以ＨＰＶ６、１１低危型为主的多型别病毒的繁殖性感染，ＣＩＮⅢ和宫颈鳞癌为ＨＰＶ１６、１８高危型病毒的整合型感染，而在ＣＩＮⅡ中存在着ＨＰＶ６，１１和ＨＰＶ１６，１８的繁殖性感染及ＨＰＶ１６，１８的整合型感染     

应用通用引物聚合酶链反应技术检测结肠癌组织中人乳头瘤病毒DNA

应用人乳头瘤病毒（ＨＰＶ）通用引物介导的聚合酶链反应（ＰＣＲ）技术检测了１５例结肠癌石蜡包埋病理组织切片中ＨＰＶＤＮＡ，其中１０例呈阳性扩增（阳性率为６６．７％）。１２例正常结肠组织经上述ＰＣＲ检测均呈阴性反应。阳性扩增产物经核酸斑点杂交进行ＨＰＶ型别分析，ＨＰＶ１６型占４例（４０．０％），１８型１例（１０．０％），１６／１８型５例（５０．０％），未检出其他ＨＰＶ型别。表明ＨＰＶ可能对结肠癌的发生具有病原相关性。     

间接法原位PCR检测喉鳞癌组织HPV感染

建立稳定的原位ＰＣＲ方法，并探讨ＨＰＶ感染与喉鳞癌发生的关系。方法采用免疫组化、原位杂变、ＰＣＲ和间接原位ＰＣＲ技术，检测了５０例喉鳞癌中的ＨＰＶ感染情况。结果免疫组化衣壳抗原阳性者６例（１２％），原位杂交阳性者１３例（２６％），ＰＣＲ阳性者１０例（２０％），原位ＰＣＲ阳性者１７例（３４％），综合上述方法的检出率为４２％（２１例）。结论ＨＰＶ感染与喉癌有着明显的关系，间接原位ＰＣＲ在检测ＨＰＶ感染     

应用量子点荧光原位杂交技术检测人宫颈鳞癌中人乳头状瘤病毒16/18的感染

目的 探讨荧光标志物量子点在荧光原位杂交技术检测人宫颈癌组织中人乳头状瘤病毒16/18(HPV16/18)感染中的应用.方法 以量子点荧光原位杂交(QD-FISH)和显色原位杂交方法(CISH)分别检测80例宫颈鳞癌活检组织中HPV16/18的感染情况,对其结果进行统计学分析.结果 QD-FISH检测宫颈鳞癌活检组织中HPV16/18阳性率为88.8%(71/80),高于CISH检出的阳性率(80%,64/80),但差异无统计学意义(P=0.127),并且HPV16/18感染的阳性率随着宫颈癌级别的上升而上升.结论 QD-FISH检测HPV感染的灵敏性和特异性均高于CISH,可作为筛查宫颈癌的一种方法.     

Genital human papilloma virus infection in Oslo studied by dot blot DNA hybridization and the polymerase chain reaction.

Samples from patients with genital condyloma acuminata or with cervical condylomas and/or dysplasia and from women without cytological/clinical evidence of cervical affection were examined by dot blot DNA hybridization or the polymerase chain reaction (PCR). The PCR was much more sensitive than dot blot, more than doubling the human papilloma virus (HPV) findings. HPV DNA, mainly HPV 6/11, was detected in 18 of 19 biopsies of condyloma acuminata, whereas HPV 16 was most frequently detected in the 21 cervices (76%) with condyloma and/or dysplasia. HPV 16 was detected in eight of 103 cervical smears with no signs of infection. The prevalence of HPV 16 in cervical samples was somewhat higher than expected. This suggests that, in Oslo, HPV 16 is a common HPV type in women with cytologically normal cervices. HPV 18 was relatively rare and was detected only in combination with other HPVs.     

宫颈脱落细胞标本中人乳头瘤病毒16、18型E6基因的检测

观察宫颈脱落细胞标本是否能替代宫颈组织标检测HPV16、18型的感染。通过聚合酶链反应－限制性片段多态性分析。比较127例宫颈患者的单、双份宫颈脱落细胞和宫颈病变组织中HPV16、18型E6基因的检出率。发现单、双份宫颈脱落细胞标本中HPV16型E6基因的检出率分别为34．64％和40．73％；HPV18型的检出率为17．32和22．04％，存在差异。组织标本中HPV16、18型的检出率分别为41．73％和22．83％，与双份脱落细胞本的检出率无明显，表明双宫颈脱落细胞标本可替代宫颈组织标本检测患者宫颈组织中HPV16、18型感染情况。     

Global Improvement in Genotyping of Human Papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study

Accurate and internationally comparable human papillomavirus (HPV) DNA genotyping is essential for HPV vaccine research and for HPV surveillance. The HPV Laboratory Network (LabNet) has designed international proficiency studies that can be issued regularly and in a reproducible manner. The 2011 HPV genotyping proficiency panel contained 43 coded samples composed of purified plasmids of 16 HPV types (HPV6, -11, -16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68a, and -68b) and 3 extraction controls. Tests that detected 50 IU of HPV16 and HPV18 and 500 genome equivalents for the other 14 HPV types in both single and multiple infections were considered proficient. Ninety-six laboratories worldwide submitted 134 data sets. Twenty-five different HPV genotyping assay methods were used, including the Linear Array, line blot/INNO-LiPA, PapilloCheck, and PCR Luminex assays. The major oncogenic HPV types, HPV16 and HPV18, were proficiently detected in 97.0% (113/116) and 87.0% (103/118) of the data sets, respectively. In 2011, 51 data sets (39%) were 100% proficient for the detection of at least one HPV type, and 37 data sets (28%) were proficient for all 16 HPV types; this was an improvement over the panel results from the 2008 and 2010 studies, when <25 data sets (23% and 19% for 2008 and 2010, respectively) were fully proficient. The improvement was also evident for the 54 laboratories that had also participated in the previous proficiency studies. In conclusion, a continuing global proficiency program has documented worldwide improvement in the comparability and reliability of HPV genotyping assay performances.     

Differences in HPV 16- and HPV 18 E6/E7 oncogene expression between in situ and invasive adenocarcinomas of the cervix uteri

To evaluate the importance of high-risk human papillomavirus (HPV) types in in situ and invasive adeno- and adenosquamous carcinomas (ACISs/ACs, and ASCISs/ASCs) of the cervix uteri, we analyzed HPV infection and HPV 16- and HPV 18 E6/E7 oncogene expression in different histologic subtypes. Using the polymerase chain reaction (PCR) technique, 29 of 33 (88%) ACISs, 2 of 2 (100%) ASCISs, 46 of 54 (85%) ACs, and 8 of 10 (80%) ASCs were found to be HPV 16- and/or HPV 18-positive. In 25 of 35 (71%), 10 of 35 (29%), and 4 of 35 (11%) ACISs/ASCISs, HPV 16, HPV 18, and HPV 16 and HPV 18 were detected, respectively. Invasive ACs/ASCs were more frequently infected with HPV 18 (36 of 64, 56%) than with HPV 16 (28 of 64, 44%). Ten (16%) of these cases were positive for HPV 16 and HPV 18. In ACISs/ASCISs, HPV 16 oncogene expression predominated (62%) relative to HPV 18 (25%) expression, whereas in invasive ACs/ASCs, only 21% of the cases expressed HPV 16, but 48% of the cases expressed HPV 18 oncogenes. Thus, detection of HPV 18 in ACISs/ASCISs might be associated with an increased risk of progression. HPV oncogene expression was not dependent on histologic subtype of in situ or invasive AC. Normal glandular epithelia and glandular dysplasias (GDs, n = 4) were always negative concerning HPV oncogene expression. In HPV 16- and HPV 18-double-infected cases, HPV 18 oncogene expression was most frequently detected, and we did not find a coexpression of HPV 16- and HPV 18-specific oncogenes in purely glandular lesions or in cases with an additional CIN (cervical intraepithelial neoplasia) II or CIN III. HPV E6/E7 expression of the same HPV type in both in situ or invasive ACs and associated CIN II/III suggest that these lesions might be histogenetically related.     

Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer

In a feasibility study using a prototype, lateral-flow test for human papillomavirus type 16, 18, and/or 45 (HPV16/18/45) E6 oncoproteins, 51 of 75 (68%; 95% confidence interval [95% CI] of 56 to 78%) of HPV16/18/45 DNA-positive specimens from women with a diagnosis of CIN3+ (cervical intraepithelial neoplasia grade 3+ or cervical cancer) tested positive for HPV16/18/45 E6 oncoprotein. None of 16 (95% CI of 0 to 37%) HPV16/18/45 DNA-positive cervical specimens from women with a negative or CIN1 diagnosis tested positive for HPV16/18/45 E6 oncoprotein.     

Detection of human papillomavirus deoxyribonucleic acid by filter in situ hybridization during pregnancy

Samples taken from 101 healthy pregnant women (49 over and 52 under the 20-week gestational period) and 108 healthy nonpregnant women were tested for human papillomavirus (HPV) types. Using 6, 11, 16, and 18 HPV DNA probes, 3-5 x 10(5) exfoliated cells scraped from the cervix were tested by filter in situ hybridization (FISH). Thirty-five of the pregnant women (34.6%) had evidence of the presence of HPV DNA: with 11.8% (12/101) HPV 6; 7.9% (8/101) HPV 11; 8.9% (9/101) HPV 16; and 5.9% (6/101) HPV 18 positivity. HPV DNA was detected in 20.4% (22/108) of the non-pregnant women. Compared with the healthy, nonpregnant group, the higher level of asymptomatic cervical HPV infection was mainly due to the accumulation of HPV 16 and 18 nucleic acids during the gestational period: with detection of HPV 16 in 8/49 cases (16.3%) and of HPV 18 DNA sequences in 4/49 (7.6%) cases. Screening 6-8 weeks after delivery indicated a decline of HPV positivity. Of the 4/12 HPV type 16 positive mothers, only one retained the presence of HPV 16 DNA, whereas neither of the 2/12 type 18 positive women reacted after birth with the type 18 radioactive probe.     

HPV typing of cervical squamous lesions by in situ HPV DNA hybridization: Influence of HPV type and therapy on the follow-up of low-grade squamous cervical disease

Papanicolaou (Pap)-stained cervical specimens from 160 squamous lesions were processed for the detection of human papillomavirus (HPV) DNA by an in situ hybridization (ISH) assay. Three biotinylated HPV DNA probes were employed, each containing HPV genotypes 6/11, HPV genotypes 16/18, or HPV genotypes 31/35/51. The HPV etiology of 86 lesions was ascertained (53.8%). In 74 out of 135 (58.8%) HPV-typed low-grade squamous intraepithelial lesions (SILs), HPV 6/11 was found in nine (6.6%), HPV 16/18 in 46 (34.2%), and HPV31/35/51 in 19 lesions (14.1%); in 11 out of 18 HPV-typed high-grade SILs (61.1%), seven lesions (38.9%) were typed for HPV 16/18 and four (22.2%) for HPV 31/35/51. Of seven invasive carcinomas, only one (14.3%) reacted with the HPV 16/18 DNA probe. A cohort of 124 low-grade SILs was followed cytologically for a year. The results of this study are discussed in light of HPV type association and therapy. Diagn Cytopathol 1994; 11:28–32. © 1994 Wiley-Liss, Inc.     

HIGH‐RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?

Since 2012, testing high‐risk (HR)HPV has been used as the primary screening test for women ≥35 years attending the organized cervical cancer screening program in the city of Tampere. We evaluated the contribution of HPV16/18 genotyping. Data from 2012 and 2013, and the follow‐up samples in 2013 and 2014, respectively, were analyzed. Abbott RealTime High‐Risk HPV test detecting 14 HRHPV genotypes combined with concurrent genotyping for HPV16 and HPV18 was used. HPV was positive in 794 samples out of 11 346 HPV tested women (7%). HPV16/18 was represented in 22% of HPV‐positive cases. Negative cervical cytology (NILM) was reported in 51% of HPV‐positive samples. HPV16/18 genotype was accompanied with 50% of HSIL/ASC‐H cases. The predominance of HPV16/18 in higher grade lesions was even more evident in cervical biopsies as 57% of CIN3 cases were associated with HPV16/18, and only 20% of carcinomas were associated with nonspecified high‐risk (NSHR) genotypes. In agreement with previous studies HPV16/18 genotypes caused higher grade cytological and histological changes/pathologies than NSHR genotypes in primary screening. Nevertheless, the majority of HRHPV genotypes detected in the screened population were nonHPV16/18, and especially within persistent infections, precancerous lesions were found also among women with NSHR genotypes.